Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Avita Therapeutics is a single product company, the RECELL system, an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes thus avoiding or reducing the need for skin grafts. The device is approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft tissue wounds and vitiligo underway. It is currently in roll-out across the approximately 136 burn centres in the U.S. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories. It is expected to gain approval and launch in Japan via distribution partner Cosmotec shortly. Avita is domiciled, and has its primary listing, in the U.S.
Los Angeles, CA, 91355